The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImperial Innovations Group Regulatory News (IVO)

  • There is currently no data for IVO

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Publication of Response Circular

1 Aug 2017 07:00

RNS Number : 6984M
Touchstone Innovations PLC
01 August 2017
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

 

 

1 August 2017

 

 

Touchstone Innovations plc

 

Publication of Response Circular in respect of the Offer by IP Group plc

 

 

The Board of Touchstone Innovations plc ("Touchstone") today announces the publication of a circular (the "Response Circular") in response to the offer by IP Group plc ("IP Group"), which was set out in the offer document published by IP Group on 18 July 2017 (the "Offer"). The Response Circular is published in accordance with Rule 25.1(a) of the City Code on Takeovers and Mergers (the "Code").

 

In accordance with the requirements of Rule 25.1(b) of the Code, a copy of the Response Circular has been made available at www.touchstoneinnovations.com. The content of the website referred to in this announcement is not incorporated into and does not form part of this announcement.

 

 

Enquiries:

 

Touchstone Innovations plc

 

Russ Cummings

Tel: +44 20 3727 2030

 

J.P. Morgan Cazenove

(Financial Adviser and Joint Corporate Broker to Touchstone

Innovations plc)

 

Michael Wentworth-Stanley

James Robinson

Alec Pratt

Tel: +44 20 7742 4000

 

RBC Capital Markets

(Joint Corporate Broker to Touchstone Innovations plc)

 

Marcus Jackson

Tel: +44 20 7653 4000

 

Instinctif Partners

 

Adrian Duffield /Melanie Toyne-Sewell/Chantal Woolcock

Tel: +44 20 7457 2020

 

Responsibility Statement

 

The directors of Touchstone each accept responsibility for the information contained in this document, except that the only responsibility accepted by them in respect of the information contained in this announcement. To the best of the knowledge and belief of each of the directors of Touchstone (who have taken all reasonable care to ensure that such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.

 

Further Information

 

J.P. Morgan Limited, which conducts its UK investment banking business as J.P. Morgan Cazenove ("J.P. Morgan Cazenove"), is authorised and regulated in the United Kingdom by the Financial Conduct Authority. J.P. Morgan Cazenove is acting as financial adviser exclusively for Touchstone and no one else in connection with the matters set out in this announcement and will not regard any other person as its client in relation to the matters in this announcement and will not be responsible to anyone other than Touchstone for providing the protections afforded to clients of J.P. Morgan Cazenove or its affiliates, or for providing advice in relation to any matter referred to herein.

 

RBC Capital Markets is the business name used by RBC Europe Limited, which is authorised in the United Kingdom by the Prudential Regulation Authority ("PRA") and regulated by the Financial Conduct Authority and the PRA and is a subsidiary of the Royal Bank of Canada. RBC is acting as Joint Corporate Broker to the Company.

 

Disclosure requirements of the Takeover Code

 

Under Rule 8.3(a) of the Takeover Code, any person who is interested in one per cent. or more of any class of relevant securities of an offeree company or of any securities exchange offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the offer period and, if later, following the announcement in which any securities exchange offeror is first identified. An Opening Position Disclosure must contain details of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 pm (London time) on the tenth Business Day following the commencement of the offer period and, if appropriate, by no later than 3.30 pm (London time) on the tenth Business Day following the announcement in which any securities exchange offeror is first identified. Relevant persons who deal in the relevant securities of the offeree company or of a securities exchange offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure.

 

Under Rule 8.3(b) of the Takeover Code, any person who is, or becomes, interested in one per cent. or more of any class of relevant securities of the offeree company or of any securities exchange offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any securities exchange offeror. A Dealing Disclosure must contain details of the dealing concerned and of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s), save to the extent that these details have previously been disclosed under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no later than 3.30 pm (London time) on the Business Day following the date of the relevant dealing.

 

If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3.

 

Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4).

 

Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Takeover Panel's website at www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the offer period commenced and when any offeror was first identified. You should contact the Panel's Market Surveillance Unit on +44 (0)20 7638 0129 if you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure.

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CIREASPFELLXEEF
Date   Source Headline
12th Dec 20123:02 pmRNSResult of AGM
16th Nov 20127:00 amRNSVeryan CE Mark approval for BioMimics 3D Stent
5th Nov 20127:00 amRNSPortfolio companies receive government funding
19th Oct 201210:00 amRNSGrant of share options
5th Oct 20127:00 amRNSFull year results
4th Oct 20127:00 amRNSCircassia initiates phase III trial
26th Sep 20127:00 amRNSPsiOxus commences clinical trial
20th Sep 201212:39 pmRNSNotice of Results
13th Sep 20123:25 pmRNSCircassia appoints Dr Brett Haumann as CMO
12th Sep 201211:35 amRNSAward Win
6th Sep 20127:00 amRNSInvestment in Cambridge technology company
1st Aug 20123:58 pmRNSDirector Dealings
23rd Jul 20127:00 amRNSInvestment in portfolio company
11th Jul 20122:50 pmRNSVeryan Medical appoints new COO and NEDs
9th Jul 20127:00 amRNS£22m funding round for PsiOxus Therapeutics
5th Jul 20125:20 pmRNSGrant of share options
27th Jun 20128:12 amRNSAbingdon Health acquires controlling stake
18th Jun 20127:00 amRNSInvestment in Oxford healthcare company
12th Jun 20127:00 amRNSInvestment in Cambridge technology company
31st May 20129:36 amRNSDirector/PDMR Shareholding
29th May 201210:05 amRNSPolytherics expands relationship with Pro Bono Bio
24th May 20127:00 amRNSDirector Dealings
1st May 20123:04 pmRNSDirector Dealings
23rd Apr 20127:00 amRNSHalf year results
26th Mar 20123:51 pmRNSNotice of Results
26th Mar 20127:00 amRNSInvestment in portfolio company
21st Mar 20127:00 amRNSDirectorate Change
8th Mar 20127:00 amRNSCircassia Phase II Clinical Trial Success
13th Feb 20127:00 amRNSInvestment in portfolio company
14th Dec 20115:27 pmRNSResult of AGM
6th Dec 20117:00 amRNSInvestment in new start-up
5th Oct 20117:00 amRNSFinal Results
27th Sep 20118:56 amRNSNotice of Results
7th Sep 20117:00 amRNSFurther investment in portfolio company
25th Aug 20117:00 amRNSInvestment in Cambridge company
22nd Aug 20117:00 amRNSInvestment in new company
3rd Aug 20117:00 amRNSInvestment in portfolio company
20th Jul 20117:00 amRNSInvestment in Stanmore
22nd Jun 20119:35 amRNSPortfolio company joint venture
19th Apr 20117:00 amRNSCircassia raises £60m
19th Apr 20117:00 amRNSHalf Yearly Report
30th Mar 201112:41 pmRNSNotice of Results
7th Feb 20116:00 pmRNSNotification of major interest in shares
3rd Feb 20118:16 amRNSDirectors' Dealings
27th Jan 20112:56 pmRNSNotification of major interest in shares
27th Jan 20112:51 pmRNSNotification of major interest in shares
26th Jan 20116:01 pmRNSNotification of major interest in shares
25th Jan 20116:03 pmRNSDirectors' Dealings
25th Jan 20115:40 pmRNSResults of Rump placing
24th Jan 20114:11 pmRNSVoting rights & share capital

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.